Mochi Health

Mochi's menu spans branded and compounded treatment options. For this publication, that makes product identification the first task. A discussion of semaglutide or tirzepatide research cannot establish the evidence for every preparation appearing beside it.

Follow the offer to the exact product

The homepage lists compounded injectable semaglutide from $60 and tirzepatide from $90, separate from a $79 monthly membership. It also carries an eligible new-subscriber promotion. These starting amounts are not universal prescriptions or total monthly treatment costs; the page says pricing and availability vary by state.

Ask which formulation the clinician would actually prescribe and which pharmacy would supply it. The FDA's concerns about unapproved GLP-1 products remain relevant even when a commercial page also discusses approved medicines. Our desk does not infer equivalence from a shared ingredient.

Read service features on another track

Mochi describes provider access, coaching and support. Those features tell a reader about the advertised care arrangement, while a trial tells a reader about the treatment and participants studied. Neither category independently verifies the other.

Medication and diagnostic services are excluded from membership. Confirm those charges before using a headline fee in a comparison. A list of available products or insurers also does not establish the outcome of a personal clinical or coverage assessment.

A useful question for the consultation

Bring the exact offer and ask what evidence applies to the proposed product and use. The mechanism-to-product guide explains why this question matters. We reviewed public materials, without testing the service or its preparations, and regard its directory position as an access option rather than a clinical ranking.